<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03721328</url>
  </required_header>
  <id_info>
    <org_study_id>JPS-001</org_study_id>
    <nct_id>NCT03721328</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy in Patients Treated for Hip or Knee PJI With Vancomycin and Tobramycin Joint Irrigation</brief_title>
  <official_title>A Phase 2 Multicenter Feasibility Trial to Evaluate Safety and Efficacy in Patients Treated for Hip or Knee Prosthetic Joint Infection With Alternating Irrigation of Vancomycin HCl and Tobramycin Sulfate in Two-Stage Exchange Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Osteal Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Osteal Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Type&#xD;
&#xD;
      Prospective, single-arm, open-label, multicenter (3 to 5 sites), interventional trial.&#xD;
&#xD;
      Primary Study Objective&#xD;
&#xD;
      The objective of the study is to determine the safety profile of local antibiotic irrigation&#xD;
      for the treatment of PJI.&#xD;
&#xD;
      Primary Outcome Measure&#xD;
&#xD;
      The overall safety profile is characterized by assessing the incidence of adverse events&#xD;
      (AEs), serious adverse events (SAEs), suspected adverse reactions, adverse reactions, and&#xD;
      unexpected adverse reactions.&#xD;
&#xD;
      Follow-up&#xD;
&#xD;
      Patients will be assessed for all measures at 3 weeks, 6 weeks, 12 weeks, and 12 months from&#xD;
      initial surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 26, 2018</start_date>
  <completion_date type="Actual">August 25, 2020</completion_date>
  <primary_completion_date type="Actual">August 25, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Evaluations</measure>
    <time_frame>12 months</time_frame>
    <description>The overall safety profile is characterized by assessing the incidence of adverse events (AEs), serious adverse events (SAEs), suspected adverse reactions, adverse reactions, and unexpected adverse reactions.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Prosthetic Joint Infection</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Joint irrigation with vancomycin and tobramycin</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>vancomycin hydrochloride and tobramycin sulfate</intervention_name>
    <description>vancomycin hydrochloride and tobramycin sulfate via local irrigation</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years or greater&#xD;
&#xD;
          -  Preoperative diagnosis of PJI of the hip or knee per the 2018 Definition of&#xD;
             Periprosthetic Hip and Knee Infection&#xD;
&#xD;
          -  Chronic PJI (symptoms lasting at least 4 weeks) per Tsukayama et al.&#xD;
&#xD;
          -  Medical clearance for surgery&#xD;
&#xD;
          -  Physical and mental ability and willingness to comply with the protocol, including the&#xD;
             ability to read and complete required forms, and willingness and ability to adhere to&#xD;
             the scheduled follow-up visits and requirements of the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Late acute hematogenous infection per Tsukayama et al.&#xD;
&#xD;
          -  Patients for whom a two-stage exchange arthroplasty is not indicated&#xD;
&#xD;
          -  Sepsis&#xD;
&#xD;
          -  Previously failed single- or two-stage revision arthroplasty for PJI (aseptic&#xD;
             revision, polyethylene liner exchange, and/or irrigation and debridement with&#xD;
             component retention is allowed)&#xD;
&#xD;
          -  Patients with PJI of more than one joint&#xD;
&#xD;
          -  Patients on chronic antibiotic therapy (≥ 6 months duration)&#xD;
&#xD;
          -  Patients who require therapeutic anticoagulation&#xD;
&#xD;
          -  Patients on antiplatelet therapy for whom withholding antiplatelet therapy for any&#xD;
             amount of time is contraindicated&#xD;
&#xD;
          -  Patients with renal insufficiency/failure (serum creatinine ≥ 2.0 mg/dl)&#xD;
&#xD;
          -  Patients with uncontrolled diabetes, defined as: hemoglobin A1C levels &gt; 8.0%&#xD;
&#xD;
          -  Patients on immunosuppressive therapy, chemotherapy for malignant disease, or&#xD;
             glucocorticoid therapy (e.g. prednisone ≥ 10 mg/day).&#xD;
&#xD;
          -  Patients with immunodeficiency (e.g., splenectomy; sickle cell anemia; Stage 3 HIV;&#xD;
             primary humoral, bone marrow, or other transplantation.)&#xD;
&#xD;
          -  Anticipated or potential patient relocation that may interfere with follow-up&#xD;
             examinations&#xD;
&#xD;
          -  Allergy to vancomycin HCl or tobramycin sulfate (Note: prior history of Red Man's&#xD;
             syndrome is not considered an allergy)&#xD;
&#xD;
          -  Patients who are pregnant or planning to become pregnant&#xD;
&#xD;
          -  Patients in whom negative pressure wound therapy is contraindicated&#xD;
&#xD;
          -  Patients infected with pathogens that are not considered susceptible to vancomycin HCl&#xD;
             or tobramycin sulfate, as per the Investigator's opinion&#xD;
&#xD;
          -  Breastfeeding at screening visit&#xD;
&#xD;
          -  Patients who are prisoners&#xD;
&#xD;
          -  Participation in another clinical trial of another Investigational Drug or&#xD;
             Investigational Device within the past 30 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bryan Springer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ortho Carolina Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covenant Hospital</name>
      <address>
        <city>Saginaw</city>
        <state>Michigan</state>
        <zip>48604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ortho Carolina Research Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SSM Health Bone and Joint Hospital at St. Anthony</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15261</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>October 17, 2018</study_first_submitted>
  <study_first_submitted_qc>October 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2018</study_first_posted>
  <last_update_submitted>September 11, 2020</last_update_submitted>
  <last_update_submitted_qc>September 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hip</keyword>
  <keyword>Knee</keyword>
  <keyword>Biofilm</keyword>
  <keyword>Minimum-biofilm-eradication-concentration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Tobramycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>September 28, 2021</submitted>
    <returned>October 19, 2021</returned>
    <submitted>November 9, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

